3 models fit UFP Technologies Inc. Common Stock and they disagree: 0 of 3 land within 15% of the average. The price is above every model.
Two or more of our models back this value.
Large premium(i)Silver69
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionUFP Technologies Inc. Common Stock (UFPT)
Fair value (3 models)
$180
ACCE price target
$305
Rating
Overvalued
Horizon
12 months
Fair value published on 19 Oct 2026, 18:04 CEST; previously $248 since 10 Oct 2026, 00:00 CEST.
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Rating published on 19 Oct 2026, 18:04 CEST.
Price used: $296 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
64.3% above
-39.1% to fair value
ACCE score
74
out of 100
Analysts
50% buy
4 covering
P/E
31.9x
forward 24.9x
1-year return
+47.7%
Dividend yield
0.00%
UFP Technologies Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
UFP Technologies makes custom foam, plastic and composite components, plus medical device contract manufacturing, mostly for OEMs in medical and life sciences, with a smaller aerospace and defense business. Its moat is qualification: once a part is designed into an FDA-regulated device, switching suppliers means revalidation and paperwork that customers avoid, which supports the 28.5% gross margin. The near-term driver is the medical segment, where the company is adding capacity and taking on more complex, higher-value assemblies as device makers outsource. Revenue growth of 15.1% alongside a 16.2% operating margin is a combination few small industrial-medical names manage, and the forward P/E of 21.8 against a trailing 32.1 suggests earnings are expected to grow into the multiple. Worth a deeper look to test whether the margin holds as acquired capacity ramps.